A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Latest Information Update: 27 Nov 2024
At a glance
- Drugs Azacitidine (Primary) ; Nadunolimab (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
Most Recent Events
- 12 Aug 2024 Status changed from planning to not yet recruiting.
- 27 Mar 2024 According to Cantargia media release, more details on the trial will be disclosed once the trial has received regulatory approval from the US FDA and relevant IRB.
- 27 Mar 2024 According to Cantargia media release, this trial is financed through a grant from the US Department of Defense (DOD). With the upcoming submission to the US FDA, the current plan is to commence the trial during the summer of 2024, pending regulatory approval.